|Bid||0.2700 x 19574500|
|Ask||0.2750 x 30420000|
|Day's range||0.2700 - 0.2800|
|52-week range||0.1850 - 0.7550|
|Beta (5Y monthly)||2.47|
|PE ratio (TTM)||N/A|
|Earnings date||29 Aug 2022 - 02 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The big shareholder groups in Incannex Healthcare Limited ( ASX:IHL ) have power over the company. Large companies...
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals.